Related Experiment Video
Updated: Jul 2, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.0K
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial
Yan Yan1,2,3, Jincheng Guo4, Xiao Wang1,2,3
1Center for Coronary Artery Disease (Y.Y., X.W., W.G., S.N.), Division of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Circulation
|February 26, 2024
Summary
Postprocedural anticoagulation (PPA) after percutaneous coronary intervention for ST-segment-elevation myocardial infarction is safe but does not reduce ischemic events. This study found no significant difference in outcomes between PPA and placebo groups.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Postprocedural anticoagulation (PPA) is common after primary percutaneous coronary intervention (PCI) for ST-segment-elevation myocardial infarction (STEMI).
- Evidence supporting routine PPA in STEMI patients undergoing primary PCI is limited and inconclusive.
- The RIGHT trial aimed to clarify the role of PPA in this patient population.
Purpose of the Study:
- To determine if postprocedural anticoagulation (PPA) reduces ischemic events in STEMI patients after primary PCI.
- To evaluate the safety of PPA by assessing major bleeding events.
- To compare the efficacy of different anticoagulation regimens (enoxaparin, unfractionated heparin, bivalirudin) within the PPA group.
Main Methods:
- A multicenter, randomized, double-blind, placebo-controlled superiority trial involving 2989 STEMI patients undergoing primary PCI.
- Patients were assigned to receive either low-dose PPA or a matching placebo for at least 48 hours.
- The primary endpoint was a composite of all-cause death, nonfatal MI, stroke, stent thrombosis, or urgent revascularization within 30 days. Safety endpoint was Bleeding Academic Research Consortium (BARC) 3-5 bleeding.
Main Results:
- The primary efficacy endpoint occurred in 2.5% of patients in both the PPA and placebo groups (HR, 1.00; 95% CI, 0.63-1.57).
- There was no significant difference in major bleeding events (BARC 3-5) between the PPA and placebo groups (0.5% vs 0.7%; HR, 0.74; 95% CI, 0.30-1.83).
- No specific PPA regimen demonstrated superiority in reducing ischemic events.
Conclusions:
- Routine postprocedural anticoagulation after primary PCI in STEMI patients is safe.
- PPA does not significantly reduce the risk of 30-day ischemic events compared to placebo.
- The practice of routine PPA in this setting is not supported by current evidence from the RIGHT trial.
